<?xml version="1.0" encoding="UTF-8"?>
<ref id="b15-1031825">
 <label>15.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Clark</surname>
    <given-names>RE</given-names>
   </name>
   <name>
    <surname>Polydoros</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Apperley</surname>
    <given-names>JF</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial</article-title>. 
  <source>Lancet Haematol</source>. 
  <year>2017</year>;
  <volume>4</volume>(
  <issue>7</issue>):
  <fpage>e310</fpage>â€“
  <lpage>e316</lpage>.
  <pub-id pub-id-type="pmid">28566209</pub-id>
 </mixed-citation>
</ref>
